In Re Pravin L. Soni, Ceinwen Rowlands, Larry Edwards and Mark Wartenberg

54 F.3d 746, 34 U.S.P.Q. 2d (BNA) 1684, 1995 U.S. App. LEXIS 10380, 1995 WL 274386
Court of Appeals for the Federal Circuit·Decided May 9, 1995·No. 94-1372·Published·Cited by 61 cases

Opinions

Opinion for the court filed by Circuit Judge LOURIE. Dissenting opinion filed by Circuit Judge MICHEL.

LOURIE, Circuit Judge.

Pravin L. Soni, Ceinwen Rowlands, Larry Edwards, and Mark Wartenberg (collectively “Soni”) appeal from the decision of the U.S. Patent and Trademark Office (“PTO”) Board of Patent Appeals and Interferences affirming the examiner’s final rejection of claims 1-6, 8-12, and 21 of application Serial No. 07/462,893, entitled “Conductive Polymer Compositions,” as unpatentable on the ground of obviousness under 35 U.S.C. § 103 (1988). Because the PTO’s conclusion that unexpected results were not shown was clearly erroneous, we reverse.

BACKGROUND

The claimed invention relates to conductive polymer compositions. Claim 1 is illustrative:

1. A melt-processed composition which comprises
(i) an organic polymer which is not eros-slinked and has a molecular weight which is greater than 150,000 when measured by high temperature gel permeation chromatography, and
(ii) a particulate conductive filler which is dispersed in the polymer and which is present in [an] amount sufficient to render the composition electrically conductive (emphasis added).

Soni’s patent specification states that the claimed compositions have significantly improved physical and electrical properties compared to compositions using polymers having a molecular weight below 150,000. To illustrate this point, the specification describes a number of tests comparing the properties of a composition of the invention composed of polyethylene having a molecular weight of 203,000 with a comparative composition composed of polyethylene having a molecular weight of 148,000. The data show at least a fifty-fold increase in tensile strength for the higher molecular weight composition compared to the lower molecular weight composition. The data also show at least a fivefold increase in peel strength as well as improved resistivity and recovery behavior properties. From these data, the specification concludes that “[t]he tensile, peel, resis[748]*748tivity behavior and recovery tests show significantly improved properties for a polymer having a molecular [weight] of 203,000 compared to one having a molecular weight of 148,000, which are much greater than would have been predicted given the difference in their molecular weights.”

During prosecution, the examiner rejected the claims over the following prior art:

Rosenzweig et al. U.S. Patent 4,775,501
Soni et al. U.S. Patent 4,921,648
Lunk et al. U.S. Patent 4,624,990
Taylor U.S. Patent 4,426,638
Wu et al. U.S. Patent 4,228,118
Capaccio et al. U.S. Patent 4,268,470
Ward et al. U.S. Patent 3,962,205

The examiner first rejected claims 1-6, 8-12, and 21 under 35 U.S.C. §§ 102 or 103 as being anticipated by or obvious from the disclosures of the Rosenzweig or Soni patents. The examiner took the position that each of these references discloses all of the limitations recited in the claims. Second, the examiner rejected claims 1-6, 8-12, and 21 under § 103 as being unpatentable over Lunk or Taylor, taken alone or in combination with Rosenzweig, Soni, Wu, Capaccio, or Ward. The examiner asserted that each of Lunk and Taylor discloses a melt-processed composition comprising an organic polymer and a particulate conductive filler. While acknowledging that Lunk and Taylor are silent as to the molecular weight of the polymers used, the examiner argued that a person of ordinary skill in the art would have selected a polymer having a molecular weight within the claimed range. Wu, Capaccio, and Ward were cited for their disclosures of melt-proeessable organic polymers having molecular weights within the claimed range.

. The rejections were subsequently made final, and Soni appealed to the Board. The Board affirmed the first rejection on the ground of § 103, but reversed it with respect to § 102. The Board found that the parent application commonly shared by Soni and Rosenzweig1 did not disclose the specific molecular weight limitation found in the claims and thus the claims were not anticipated by Soni or Rosenzweig under § 102(a) or (e). The Board found, however, that

[i]f higher molecular weight melt-processable polymers were not available at the time the parent application was filed, they certainly became available by the time of appellants’ invention, as evidenced by appellants’ acknowledgements in the present specification, i.e., that the compositions in the appealed claims are based on commercially available polymers. It is also acknowledged on this record that one of ordinary skill in the relevant art would have expected higher molecular weight polymers to result in better composition properties. See the present specification at page 17, lines 22 to 28. On this record, it would have constituted nothing more than the exercise of ordinary skill for one to have selected commercially available higher molecular weight polymers to use in the melt-processes of the references to obtain advantageous physical properties in the resulting product (emphasis added).

In response to Soni’s argument that its specification describes unexpected results, the Board stated:

In the referenced portion of the present specification, it is also asserted that the improvement in properties resulting from the use of the specific class of molecular weights set forth in appellants’ claims was “much greater than would have been predicted.” However, this record appears to be devoid of any evidence to support that conclusion. Thus, to whatever extent it may be considered that there is any evidence of unobviousness, it is clearly insufficient to outweigh the evidence of obviousness of record (emphasis added).

The Board also affirmed the § 103 rejection based on Lunk or Taylor, taken alone or in combination with the other references cited by the examiner. The Board found that Lunk would have anticipated the claimed invention except that the reference does not explicitly disclose polymers having a molecular weight greater than 150,000. The Board further found that

selection of a specific molecular weight from within the very high molecular [749]*749weight class disclosed by Lunk would have been obvious to one of ordinary skill in the relevant art, and there is no convincing evidence that unobvious results are associated with the specific molecular weight limitation in question. Similarly, there is no evidence that substitution of other well-known melt-processable polymers in the Lunk composition produces unobvious results.

The Board noted that this analysis applied equally to the Taylor reference and found the remaining references essentially superfluous in view of Lunk or Taylor.

Soni requested reconsideration of the Board’s decision, arguing that the Board ignored the evidence of unexpected results disclosed in the specification. On reconsideration, the Board adhered to its decision:

Free access — add to your briefcase to read the full text and ask questions with AI

In Re Pravin L. Soni, Ceinwen Rowlands, Larry Edwards and Mark Wartenberg, 54 F.3d 746, 34 U.S.P.Q. 2d (BNA) 1684, 1995 U.S. App. LEXIS 10380, 1995 WL 274386 (Fed. Cir. 1995).

54 F.3d 746 (In Re Pravin L. Soni, Ceinwen Rowlands, Larry Edwards and Mark Wartenberg) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

FullView, Inc. v. Polycom, Inc.
N.D. California, 2022
BTG Int'l Ltd. v. Amneal Pharm. LLC
352 F. Supp. 3d 352 (D. New Jersey, 2018)
Millennium Pharmaceuticals, Inc. v. Sandoz Inc.
862 F.3d 1356 (Federal Circuit, 2017)
In Re: Ethicon, Inc.
844 F.3d 1344 (Federal Circuit, 2017)
Securitypoint Holdings, Inc. v. United States
129 Fed. Cl. 25 (Federal Claims, 2016)
Trustees of Columbia University v. Illumina, Inc.
620 F. App'x 916 (Federal Circuit, 2015)
Warner Chilcott Co. v. Teva Pharmaceuticals USA, Inc.
89 F. Supp. 3d 641 (D. New Jersey, 2015)
Numatics, Inc. v. Balluff, Inc.
66 F. Supp. 3d 934 (E.D. Michigan, 2014)
Par Pharmaceutical, Inc. v. Twi Pharmaceuticals, Inc.
773 F.3d 1186 (Federal Circuit, 2014)
In Re: Rajen Patel
566 F. App'x 1005 (Federal Circuit, 2014)
Hoffmann-La Roche Inc. v. Apotex Inc.
748 F.3d 1326 (Federal Circuit, 2014)
Galderma Laboratories, L.P. v. Tolmar, Inc.
737 F.3d 731 (Federal Circuit, 2013)
Leo Pharmaceutical Products, Ltd. v. Rea
726 F.3d 1346 (Federal Circuit, 2013)
Allergan, Inc. v. Sandoz Inc.
726 F.3d 1286 (Federal Circuit, 2013)
Bristol-Myers Squibb Co. v. Teva Pharmaceuticals USA, Inc.
923 F. Supp. 2d 602 (D. Delaware, 2013)
Alcon Research, Ltd. v. Apotex Inc.
790 F. Supp. 2d 868 (S.D. Indiana, 2011)